Introduction
============

Neuroblastoma, a solid tumor of the sympathetic nervous system, remains the most commonly occurring lethal cancer among children \[[@r1]\], accounting for 7%-10% of all cancers in children under 15 years of age \[[@r2],[@r3]\]. The prevalence of neuroblastoma in the United States is about 1 in 7000 \[[@r4]\], but is only about 1 in 13,000 in China \[[@r5]\]. Neuroblastomas have been classified into low-risk, intermediate-risk and high-risk groups \[[@r6]\]. Among them, the high-risk group accounts for 50% of all neuroblastoma patients. The 5-year survival rate among this high-risk group remains less than 35%, despite administration of intense multimodal therapy \[[@r7],[@r8]\]. This low cure rate may be attributable to the presence of widespread tumor metastasis at the time of diagnosis \[[@r9]\].

About 1% of neuroblastoma patients present with hereditary disease \[[@r10]\]. The etiology of familial neuroblastoma is mainly explained by germline mutations in *PHOX2B* \[[@r11],[@r12]\] and *ALK* \[[@r13],[@r14]\]. Although, there is as yet no explicit description of the causes of sporadic neuroblastoma, there is growing evidence suggesting genetic and genetic-environmental factors affect ones susceptibility to neuroblastoma \[[@r15],[@r16]\]. Recent genome-wide association studies identified DNA alleles that contribute significantly to the risk of neuroblastoma, including *BARD1* \[[@r17]\], *TP53* \[[@r18]\], *HACE1* \[[@r19]\], *LIN28B* \[[@r19]\], and *MMP20* \[[@r20]\]. Moreover, candidate gene approaches also associated *NEFL* \[[@r21]\] and *CDKN1B* \[[@r22]\] polymorphisms with neuroblastoma susceptibility.

The integrity and stability of the human genome is maintained primarily by DNA repair systems \[[@r23]\], among which the nucleotide excision repair (NER) pathway is essential in eliminating DNA damage caused by both exogenous and endogenous factors \[[@r24]\]. Dysfunction of the NER pathway could lead to failure to repair genomic defects, thereby increasing cancer risk \[[@r25]--[@r27]\]. Several critical genes (*ERCC1*, *XPA*, *XPB*, *XPC*, *XPD*, *XPE*, *XPF* and *XPG*) participate in the NER process and coordinately function to maintain genomic integrity \[[@r28]\]. *XPD* (xeroderma pigmentosum complementary group D), also known as *ERCC2* (excision repair cross-complementation group 2), encodes an evolutionarily conserved ATP-dependent helicase \[[@r29]\]. This helicase forms a complex with the transcription factor TFIIH to function in basal transcription and nucleotide excision repair \[[@r30]\]. The importance of *XPD* to the NER pathway has prompted several case-control studies to assess the effect of *XPD* polymorphisms on the risk of such cancers as nasopharyngeal carcinoma \[[@r31]\], renal cell carcinoma \[[@r32]\], prostate cancer \[[@r33]\], esophageal squamous cell carcinoma \[[@r34]\], and breast cancer \[[@r35]\]. However, the effect of *XPD* polymorphisms on neuroblastoma risk has not yet been studied. To address that issue, we conducted a four-center case-control study analyzing the relationship between three *XPD* polymorphisms and neuroblastoma risk in the Chinese population.

RESULTS
=======

Correlation between *XPD* polymorphisms and neuroblastoma susceptibility
------------------------------------------------------------------------

A total of 505 patients and 1070 healthy controls were successfully genotyped in our study. The demographic characteristics of the tested subjects can be found in our previously published articles \[[@r36]--[@r39]\] and in [Supplemental Table 1](#SD1){ref-type="supplementary-material"}. The genotype frequencies for the three selected *XPD* polymorphisms (rs3810366, rs13181, rs238406) in all subjects and in selected subject groups and their contributions to neuroblastoma risk are summarized in [Table 1](#t1){ref-type="table"} and [Supplemental Table 2](#SD2){ref-type="supplementary-material"}. No single *XPD* polymorphism was significantly associated with neuroblastoma risk in any genetic model evaluated. On the other hand, participants harboring 2 or 3 risk genotypes were more likely to develop neuroblastoma (adjusted OR=1.31; 95% CI=1.06-1.62, *P*=0.013) than those with 0 or 1 risk genotype.

###### Logistic regression analysis of the correlation between *XPD* polymorphisms and neuroblastoma risk.

  --------------------------------------- ------------- -------------- --------- ---------------------- ----------- ---------------------- -----------
  Genotype                                Cases\        Controls\      *P* ^a^   Crude OR\              *P*         Adjusted OR\           *P* ^b^
                                          (N=505)       (N=1070)                 (95% CI)                           (95% CI) ^b^           

  rs3810366 (HWE=0.143)                                                                                                                    

  GG                                      118 (23.37)   285 (26.64)              1.00                               1.00                   

  GC                                      261 (51.68)   511 (47.76)              1.23 (0.95-1.60)       0.115       1.23 (0.95-1.60)       0.120

  CC                                      126 (24.95)   274 (25.61)              1.11 (0.82-1.50)       0.494       1.11 (0.82-1.50)       0.502

  Additive                                                             0.277     1.05 (0.91-1.22)       0.498       1.05 (0.91-1.22)       0.506

  Dominant                                387 (76.63)   785 (73.36)    0.165     1.19 (0.93-1.52)       0.166       1.19 (0.93-1.52)       0.171

  Recessive                               379 (75.05)   796 (74.39)    0.780     0.97 (0.76-1.23)       0.781       0.97 (0.76-1.23)       0.778

  rs13181 (HWE=0.971)                                                                                                                      

  TT                                      424 (83.96)   905 (84.58)              1.00                               1.00                   

  TG                                      75 (14.85)    158 (14.77)              1.01 (0.75-1.37)       0.931       1.01 (0.75-1.36)       0.943

  GG                                      6 (1.19)      7 (0.65)                 1.83 (0.61-5.48)       0.280       1.84 (0.61-5.50)       0.278

  Additive                                                             0.548     1.08 (0.83-1.41)       0.586       1.08 (0.82-1.40)       0.594

  Dominant                                81 (16.04)    165 (15.42)    0.752     1.05 (0.78-1.40)       0.751       1.05 (0.78-1.40)       0.762

  Recessive                               499 (98.81)   1063 (99.35)   0.274     1.83 (0.61-5.46)       0.281       1.83 (0.61-5.49)       0.279

  rs238406 (HWE=0.325)                                                                                                                     

  GG                                      133 (26.34)   317 (29.63)              1.00                               1.00                   

  GT                                      264 (52.28)   516 (48.22)              1.22 (0.95-1.57)       0.121       1.22 (0.95-1.57)       0.119

  TT                                      108 (21.39)   237 (22.15)              1.09 (0.80-1.47)       0.595       1.09 (0.80-1.48)       0.578

  Additive                                                             0.282     1.05 (0.91-1.22)       0.508       1.05 (0.91-1.22)       0.492

  Dominant                                372 (73.66)   753 (70.37)    0.177     1.18 (0.93-1.49)       0.178       1.18 (0.93-1.50)       0.172

  Recessive                               397 (78.61)   833 (77.85)    0.732     0.96 (0.74-1.24)       0.734       0.96 (0.74-1.24)       0.749

  Combined effect of risk genotypes ^c^                                                                                                    

  0-1                                     247 (48.91)   595 (55.61)              1.00                               1.00                   

  2-3                                     258 (51.09)   475 (44.39)    0.013     **1.31 (1.06-1.62)**   **0.013**   **1.31 (1.06-1.62)**   **0.013**
  --------------------------------------- ------------- -------------- --------- ---------------------- ----------- ---------------------- -----------

^a^ *χ^2^* test for genotype distributions between neuroblastoma patients and cancer-free controls. ^b^ Adjusted for age and gender. ^c^ Risk genotypes were rs3810366 GC/GG, rs13181 GG and rs238406 GT/TT.

Stratification analysis of *XPD* polymorphisms and neuroblastoma susceptibility
-------------------------------------------------------------------------------

To assess the correlations between *XPD* polymorphisms and neuroblastoma risk in particular subgroups of healthy individuals and neuroblastoma patients, we conducted analyses after stratifying based on age, gender, sites of origin, and clinical stages. We found a significant association between the rs3810366 GC/CC genotypes and neuroblastoma risk in participants under age ≤18 months (adjusted OR=1.66, 95% CI=1.10-2.49, *P*=0.015) and in the clinical stage I+II+4s subgroup (adjusted OR=1.50, 95% CI=1.06-1.11, *P*=0.021) ([Table 2](#t2){ref-type="table"}). After combining the risk genotypes ([Table 2](#t2){ref-type="table"}), we observed that patients in the following subgroups with 2-3 risk genotypes were more likely to develop a tumor: age ≤18 months (adjusted OR=1.43, 95% CI=1.02-2.02, *P*=0.041), male (adjusted OR=1.33, 95% CI=1.01-1.76, *P*=0.046), tumor originated from others (adjusted OR=2.29, 95% CI=1.20-4.36, *P*=0.012), and clinical stage I+II+4s (adjusted OR=1.53, 95% CI=1.16-2.01, *P*=0.003). We then performed haplotype analysis to determine whether any haplotype carriers were more likely to develop neuroblastoma ([Table 3](#t3){ref-type="table"}). However, no *XPD* haplotype was associated with neuroblastoma susceptibility when the most common haplotype (GTG) was used as the reference.

###### Stratification analysis of associations between *XPD* genotypes and neuroblastoma susceptibility.

  ----------------- ---------------- ---------------- ---------------------- ---------------- ---------------- -------- ------------------ ---------------- -------- ----------------- ------------------ -------- --------- --------- ---------------------- -----------
  Variables         rs3810366\       Adjusted OR^a^   *P*^a^                 rs13181\         Adjusted OR^a^   *P*^a^   rs238406\          Adjusted OR^a^   *P*^a^   Risk genotypes\   Adjusted OR^a^     *P*^a^                                              
                    (case/control)                                           (case/control)                             (case/control)                               (case/control)                                                                           

                    GG               GC/CC            (95% CI)                                TT               TG/GG    (95% CI)                            GG       GT/TT             (95% CI)                    0-1       2-3       (95% CI)               

  Age, month                                                                                                                                                                                                                                                  

  ≤18               40/130           149/295          **1.66 (1.10-2.49)**   **0.015**        156/361          33/64    1.19 (0.75-1.88)   0.464            55/124   134/301           1.00 (0.69-1.46)   0.997    94/249    95/176    **1.43 (1.02-2.02)**   **0.041**

  \>18              78/155           238/490          0.96 (0.70-1.32)       0.804            268/544          48/101   0.96 (0.66-1.40)   0.829            78/193   238/452           1.31 (0.96-1.78)   0.085    153/346   163/299   1.24 (0.94-1.62)       0.125

  Gender                                                                                                                                                                                                                                                      

  Female            46/109           167/339          1.17 (0.79-1.73)       0.440            182/373          31/75    0.85 (0.54-1.34)   0.478            61/142   152/306           1.16 (0.81-1.65)   0.427    106/250   107/198   1.27 (0.92-1.77)       0.147

  Male              72/176           220/446          1.20 (0.87-1.65)       0.270            242/532          50/90    1.22 (0.84-1.78)   0.305            72/175   220/447           1.20 (0.87-1.65)   0.258    141/345   151/277   **1.33 (1.01-1.76)**   **0.046**

  Sites of origin                                                                                                                                                                                                                                             

  Adrenal gland     38/285           135/785          1.27 (0.86-1.86)       0.231            149/905          24/165   0.86 (0.54-1.37)   0.529            48/317   125/753           1.12 (0.78-1.61)   0.534    86/595    87/475    1.28 (0.92-1.76)       0.140

  Retroperitoneal   41/285           106/785          0.96 (0.65-1.42)       0.850            126/905          21/165   0.93 (0.57-1.53)   0.785            35/317   112/753           1.32 (0.88-1.98)   0.175    74/595    73/475    1.24 (0.87-1.75)       0.227

  Mediastinum       32/285           103/785          1.16 (0.76-1.77)       0.489            107/905          28/165   1.44 (0.92-2.25)   0.113            42/317   93/753            0.94 (0.64-1.39)   0.768    72/595    63/475    1.11 (0.77-1.58)       0.586

  Others            7/285            35/785           1.89 (0.83-4.30)       0.132            36/905           6/165    0.92 (0.38-2.22)   0.854            8/317    34/753            1.77 (0.81-3.86)   0.153    15/595    27/475    **2.29 (1.20-4.36)**   **0.012**

  Clinical stage                                                                                                                                                                                                                                              

  I+II+4s           49/285           201/785          **1.50 (1.06-2.11)**   **0.021**        215/905          35/165   0.90 (0.61-1.33)   0.589            65/317   185/753           1.20 (0.88-1.64)   0.253    113/595   137/475   **1.53 (1.16-2.01)**   **0.003**

  III+IV            62/285           170/785          0.96 (0.70-1.33)       0.823            196/905          36/165   0.98 (0.66-1.46)   0.920            66/317   166/753           1.08 (0.79-1.48)   0.642    126/595   106/475   1.04 (0.78-1.39)       0.768
  ----------------- ---------------- ---------------- ---------------------- ---------------- ---------------- -------- ------------------ ---------------- -------- ----------------- ------------------ -------- --------- --------- ---------------------- -----------

^a^ Adjusted for age and gender, omitting the corresponding stratification factor.

###### Association between inferred *XPD* haplotypes and neuroblastoma susceptibility.

  ---------------- ------------- ------------- ------------------ ------- ------------------ ---------
  Haplotypes ^a^   Cases\        Controls\     Crude OR\          *P*     Adjusted OR ^b^\   *P* ^b^
                   (n=1010)      (n=2140)      (95% CI)                   (95% CI)           

  GTG              267 (26.44)   553 (25.84)   1.00                       1.00               

  GTT              203 (20.10)   470 (21.96)   0.90 (0.72-1.12)   0.321   0.90 (0.72-1.12)   0.340

  GGG              6 (0.59)      7 (0.33)      1.78 (0.59-5.33)   0.307   1.80 (0.60-5.42)   0.295

  GGT              21 (2.08)     51 (2.38)     0.85 (0.50-1.45)   0.555   0.85 (0.50-1.44)   0.544

  CTG              230 (22.77)   527 (24.63)   0.90 (0.73-1.12)   0.352   0.91 (0.73-1.12)   0.357

  CTT              223 (22.08)   418 (19.53)   1.11 (0.89-1.38)   0.371   1.11 (0.89-1.38)   0.370

  CGG              27 (2.67)     63 (2.94)     0.89 (0.55-1.43)   0.622   0.88 (0.55-1.42)   0.602

  CGT              33 (3.27)     51 (2.38)     1.34 (0.85-2.13)   0.214   1.35 (0.85-2.14)   0.202
  ---------------- ------------- ------------- ------------------ ------- ------------------ ---------

^a^ The haplotype order was rs3810366, rs13181, and rs238406. ^b^ Adjusted for age and gender.

DISCUSSION
==========

To identify *XPD* polymorphisms influencing neuroblastoma tumorigenesis, we performed a hospital-based case-control study involving a total of 505 neuroblastoma patients and 1070 healthy control subjects. All participants were Chinese. To our knowledge, this study is the first investigation assessing the association between *XPD* polymorphisms and neuroblastoma risk in Chinese children.

*XPD* is located on chromosome 19p13.3 \[[@r40]\] and is composed of 23 exons encoding an evolutionarily conserved ATP-dependent helicase. This helicase is responsible for DNA unwinding and transcription initiation. More than 100 mutations have been mapped in *XPD* \[[@r41]\], which could potentially affect the helicase activity of the encoded protein, thereby impeding normal NER function and leading to increased cancer risk \[[@r29],[@r42]\]. Several *XPD* polymorphisms are reportedly associated with cancer risk \[[@r43]--[@r45]\]. Among these, rs1799793 (Asp312Asn) and rs13181 (Lys751Gln) in the *XPD* coding region are the two most widely investigated. The rs13181 polymorphism at codon 751 in exon 23 is a non-synonymous A\>C substitution, which results in an amino acid change from Lys to Gln. It has been demonstrated that this Lys751Gln polymorphism could decrease DNA repair capacity \[[@r46]\]. In a study conducted in Poland with 430 patients and 430 controls, Magdalena et al. \[[@r47]\] found that the Gln/Gln genotype of rs13181 is associated with an increased risk of ovarian cancer. In our earlier study investigation of the association between two *XPD* polymorphisms (rs238406 and rs13181) and esophageal squamous cell carcinomas risk, we found that rs238406, but not rs13181, was associated with elevated disease risk \[[@r34]\]. The results are somewhat inconclusive, however, since differing relationships between *XPD* polymorphisms and cancer risk have been reported. These discrepancies may reflect differences in the cancer types, sample sizes, population sources, selection criteria for subjects, and environmental exposures. It is therefore necessary to limit conclusions regarding the contributions of *XPD* polymorphisms to cancer risk to a particular population and cancer type.

Given the critical role of *XPD* polymorphisms in cancer risk and the lack of research on their contributions to neuroblastoma risk, we endeavored to assess the association between three *XPD* polymorphisms and neuroblastoma risk in Chinese children. Unexpectedly, we failed to detect any significant contribution by rs13181 or rs238406 to neuroblastoma risk in the overall analysis or in any of the selected subgroups after stratification. Several factors, including the relatively small sample size, low penetrance of a single polymorphism, and population bias may account for the null association. The etiology of neuroblastoma is complex and subject to heterogenetic influence by a variety of risk factors \[[@r15],[@r48]\]. Although a single *XPD* polymorphism may have limited impact on neuroblastoma risk, it would be expected that the combined effects of several polymorphisms might bring about more significant findings. Indeed, in the present study, we observed that participants with two or more risk genotypes of these functional *XPD* polymorphisms were at significantly higher risk of neuroblastoma than those carrying one or fewer risk genotypes. This trend was also observed in earlier studies by ourselves and others \[[@r49],[@r50]\]. These findings are biologically plausible, probably due to the joint effects of multiple functional polymorphisms.

While this study has its merits, it also has several limitations. First, inherent bias could not be excluded, as all the DNA samples were collected in hospitals. Second, although the sample size for the overall analysis was relatively large, after stratification some subgroups were less than 100, which inevitably diminished the statistical power. Third, the included subjects were restricted to unrelated Han Chinese; consequently, the results may not be applicable to other ethnicities. Fourth, only three *XPD* polymorphisms were selected and analyzed in this study. Other potentially functional *XPD* polymorphisms may also modify the activity of gene or the encoded helicase and thus should be involved in the ongoing study. Fifth, as neuroblastoma is a heterogeneous disease with a complex etiology, the genetic analysis in the present study only partially elucidated the etiology of neuroblastoma. Potentially important environmental factors such as diet, living environment, and parental exposures should be addressed in the future.

In summary, our findings provide insight into the potential role of *XPD* polymorphisms in neuroblastoma risk. Our results failed to detect a role for any single *XPD* polymorphism in neuroblastoma risk. It is anticipated that ongoing epidemiological studies with larger samples and more analysis of confounding factors will provide additional information on the contribution of *XPD* polymorphisms to neuroblastoma tumorigenesis.

MATERIALS AND METHODS
=====================

Study subjects
--------------

A total of 505 cases and 1070 healthy controls were included in this study. Of those, 429 cases and 884 controls were described in our previous study \[[@r39]\]. The additional 76 cases and 186 controls were from the Second Affiliated Hospital of Xi\'an Jiaotong University ([Supplemental Table 1](#SD1){ref-type="supplementary-material"}). The cases were individuals diagnosed with neuroblastoma, and the controls were recruited from the same hospitals between September 2009 and March 2018. The eligibility criteria for the included subjects were described previously \[[@r49],[@r51]--[@r53]\]. Written informed consent was provided by all subjects or their guardians. The study protocols were approved by the Institutional Review Board of each hospital.

Polymorphism selection and genotyping
-------------------------------------

In brief, we searched for potentially functional candidate SNPs located in the 5'- flanking region, 5' untranslated region, 3' untranslated region, and exon of *XPD*. The potentially functional *XPD* polymorphisms were screened from the NCBI dbSNP database (<http://www.ncbi.nlm.nih.gov/projects/SNP>) and SNPinfo (<http://snpinfo.niehs.nih.gov/snpfunc.htm>) using previously described criteria \[[@r54]\]. Three polymorphisms (rs3810366 G\>C, rs13181 T\>G, and rs238406 G\>T) in the *XPD* gene were ultimately selected: rs3810366 G\>C, which is located within transcription factor binding sites; rs13181 T\>G and rs238406 G\>T, which may affect splicing regulation activity; and rs13181 T\>G, which may also lead to Lys751Gln alteration. As shown in [Supplementary Figure 1](#SD3){ref-type="supplementary-material"}, there was no significant LD (R^2^\<0.8) between rs13181 and rs238406 (R^2^=0.026) or between rs13181 and rs3810366 (R^2^=0.001). However, there was a little LD between rs238406 and rs3810366 (R^2^=0.891).

For genotyping, DNA samples were mainly purified from venous blood using a TIANamp Blood DNA Kit (TianGen Biotech Co. Ltd., Beijing, China). Following standard methods, we used TaqMan real-time PCR to genotype the selected polymorphisms. Details of the genotyping protocol are provided elsewhere \[[@r54]--[@r57]\]. To control for result quality, approximately 10% of the samples were randomly selected to perform duplicate analyses. We obtained a concordance rate of 100% for all duplicate sets.

Statistical analysis
--------------------

We first used a goodness-of-fit χ^2^ test to assess whether the selected polymorphisms were in Hardy-Weinberg equilibrium in the controls. The demographic variables and allele frequencies were compared between the cases and controls using a two-sided χ^2^ test. The association between *XPD* polymorphisms and neuroblastoma risk was estimated using logistic regression analysis providing odds ratios (ORs) and 95% confidence intervals (CIs). Values of *P*\<0.05 were considered significant. All statistical analyses were performed using the SAS statistical package (version 9.1, SAS Institute, Cary, NC).
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